A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
NCT ID: NCT04934618
Last Updated: 2021-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
85 participants
INTERVENTIONAL
2020-05-19
2025-05-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer
NCT05342389
Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.
NCT03144843
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
NCT05029453
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
NCT07085273
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05024812
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carelizumab Combined With Irinotecan and Apatinib
Second-line treatment of advanced gastric cancer with three-drug regimen（Carelizumab Combined With Irinotecan and Apatinib ）
Carelizumab Combined With Irinotecan and Apatinib
Three-drug regimen was used in second-line treatment of Advanced gastric cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carelizumab Combined With Irinotecan and Apatinib
Three-drug regimen was used in second-line treatment of Advanced gastric cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. After receiving first-line treatment, the disease progressed or intolerable adverse reactions occurred.
3. At least one measurable lesion or evaluable lesion (according to RECIST 1.1 standard);
4. Patients agreed to provide blood samples and previously stored tumor tissue samples for tumor microenvironment detection.
5. Age ≥18 years old and ≤75 years old.
6. The ECOG score is 0 or 1.
7. The estimated survival time is ≥3 months.
8. Within 7 days before entering the group, the laboratory test value met the chemotherapy standard.
9. Within 28 days before enrollment, women of childbearing age must confirm that the serum pregnancy test is negative and agree to adopt effective contraceptive measures during the study drug use and within 6 months after the last administration.
10. Patients voluntarily joined the study, signed informed consent, and were able to comply with the visit and related procedures stipulated in the plan.
Exclusion Criteria
2. have received antibody therapy of PD-1, PD-L1, PD-L2, CTLA4, CD137 or any other antibody or drug therapy with t cell co-stimulation or immune checkpoint pathway as specific target.
3. It is known to be allergic to any monoclonal antibody or adjuvant.
4. Received Chinese patent medicines with anti-tumor indications or drugs with immunoregulatory effects (thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration.
5. Having undergone major surgery within 4 weeks before the first administration or expecting to undergo surgery during the study treatment.
6. Receive live attenuated vaccine within 4 weeks before the first administration or during the planned study treatment.
7. Received transplantation of solid organs or blood system.
8. Active, known or suspected autoimmune diseases or related medical history in the past 2 years (vitiligo, psoriasis, alopecia or Graves' disease that does not require systematic treatment in the past 2 years, hypothyroidism that only requires thyroid hormone replacement therapy, and type I diabetes patients who only need insulin replacement therapy can enter Group).
9. Immunosuppressive drugs have been used within 4 weeks before the first administration, excluding local glucocorticoid by nasal spray, inhalation or other routes or systemic glucocorticoid with physiological dose (i.e., prednisone or other glucocorticoid with equivalent dose not exceeding 10mg/ day), or hormone used due to allergy.
10. Known history of primary immunodeficiency disease.
11. Known history of active tuberculosis. 12 known to have a history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive).
13\. after regular antihypertensive treatment, the blood pressure still cannot fall to the normal range (systolic blood pressure \> \>140mmHg, diastolic blood pressure \> \>90mmHg).
14\. ≥II grade ii coronary heart disease and arrhythmia (including QTc interval prolongation \> \>450ms for men and \> \>470ms for women).
15\. Symptomatic congestive heart failure (new york Heart Association Grade II-IV) or symptomatic or poorly controlled arrhythmia.
16\. before the first administration, there was toxicity caused by previous anti-tumor treatment that did not recover to grade 0 or grade 1 of the national cancer institute general adverse event terminology version 4.03 (NCI ctcae version 4.03) (excluding alopecia, fatigue and asymptomatic laboratory abnormalities).
17\. abnormal coagulation function (INR \> 1.5 uln, aptt \> 1.5 uln), with bleeding tendency.
18\. It is known that symptomatic central nervous system metastasis exists. 19. Diagnosed as other malignant tumors within 5 years before the first administration, excluding basal cell carcinoma of skin, squamous cell carcinoma of skin and carcinoma in situ after radical resection.
20\. Active infections requiring treatment or systemic anti-infective drugs used within 7 days before the first administration.
21\. acute or chronic active hepatitis b: HBV viral load ≥500 copies /ml 22. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before the study.
23\. It is known that there are mental diseases or drug abuse situations that may affect the compliance with the test requirements.
24\. Acute or chronic active hepatitis C: HCV antibody is positive. 25. Pregnant or lactating women. 26. There are medical histories, diseases, treatments or abnormal laboratory results that may interfere with the test results and prevent the subjects from participating in the study, or the researchers think that participating in the study is not in the best interests of the subjects.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shimin
Vice director of Oncology Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Min Shi
Role: PRINCIPAL_INVESTIGATOR
Oncology department of Nanfang hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NanFang Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NFEC-2020-024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.